• Je něco špatně v tomto záznamu ?

Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes

R. Vrzal, L. Stejskalová, K. Monostory, P. Maurel, P. Bachleda, P. Pávek, Z. Dvořák

. 2009 ; 179 (2-3) : 288-296.

Jazyk angličtina Země Irsko

Perzistentní odkaz   https://www.medvik.cz/link/bmc11009506

CYP1A1 and CYP1A2 genes encode members of the cytochrome P450 superfamily of enzymes primarily involved in xenobiotic and drug metabolism. In this paper we examined the effects of synthetic glucocorticoid dexamethasone (DEX) on aryl hydrocarbon receptor (AhR)-mediated regulation of CYP1A1 and CYP1A2 genes and their enzymatic activity in primary cultures of human hepatocytes obtained from 17 donors and prepared in 3 countries. Dexamethasone significantly reduced both basal and inducible CYP1A1/2 ethoxyresorufin-O-deethylase (EROD) activities by more than 75 and 50%, respectively. Glucocorticoid receptor (GR) antagonist RU486 abolished this effect suggesting the involvement of GR in the process. In contrast, dexamethasone significantly augmented transcriptional activation of CYP1A2 mRNA but not CYP1A1 gene by prototype AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 3-methylcholanthrene (3MC). Dexamethasone had no effect on basal and TCDD-inducible levels of CYP1As proteins; however, it reduced the levels of AhR and GRalpha mRNAs and AhR protein levels. In addition, using RT(2) Profiler PCR Array, we found the effect of dexamethasone on the expression of several co-activators of AhR and GR nuclear receptors in the primary human hepatocytes. We conclude that dexamethasone controls CYP1A1 and CYP1A2 expression and activity in human hepatocytes via multiple mechanisms, which remain to be elucidated.

000      
03758naa 2200601 a 4500
001      
bmc11009506
003      
CZ-PrNML
005      
20111210204221.0
008      
110510s2009 ie e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Vrzal, Radim $7 xx0118949
245    10
$a Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes / $c R. Vrzal, L. Stejskalová, K. Monostory, P. Maurel, P. Bachleda, P. Pávek, Z. Dvořák
314    __
$a Department of Cell Biology and Genetic, Faculty of Science, Palacky University, Slechtitelu 11, 783 71 Olomouc, Czech Republic.
520    9_
$a CYP1A1 and CYP1A2 genes encode members of the cytochrome P450 superfamily of enzymes primarily involved in xenobiotic and drug metabolism. In this paper we examined the effects of synthetic glucocorticoid dexamethasone (DEX) on aryl hydrocarbon receptor (AhR)-mediated regulation of CYP1A1 and CYP1A2 genes and their enzymatic activity in primary cultures of human hepatocytes obtained from 17 donors and prepared in 3 countries. Dexamethasone significantly reduced both basal and inducible CYP1A1/2 ethoxyresorufin-O-deethylase (EROD) activities by more than 75 and 50%, respectively. Glucocorticoid receptor (GR) antagonist RU486 abolished this effect suggesting the involvement of GR in the process. In contrast, dexamethasone significantly augmented transcriptional activation of CYP1A2 mRNA but not CYP1A1 gene by prototype AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 3-methylcholanthrene (3MC). Dexamethasone had no effect on basal and TCDD-inducible levels of CYP1As proteins; however, it reduced the levels of AhR and GRalpha mRNAs and AhR protein levels. In addition, using RT(2) Profiler PCR Array, we found the effect of dexamethasone on the expression of several co-activators of AhR and GR nuclear receptors in the primary human hepatocytes. We conclude that dexamethasone controls CYP1A1 and CYP1A2 expression and activity in human hepatocytes via multiple mechanisms, which remain to be elucidated.
590    __
$a bohemika - dle Pubmed
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a kultivované buňky $7 D002478
650    _2
$a cytochrom P-450 CYP1A1 $x genetika $x metabolismus $7 D019363
650    _2
$a cytochrom P-450 CYP1A2 $x genetika $x metabolismus $7 D019388
650    _2
$a dexamethason $x farmakologie $7 D003907
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese enzymů $x účinky léků $7 D015971
650    _2
$a hepatocyty $x enzymologie $x metabolismus $x účinky léků $7 D022781
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methylcholanthren $x toxicita $7 D008748
650    _2
$a lidé středního věku $7 D008875
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a receptory aromatických uhlovodíků $x metabolismus $7 D018336
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a polychlorované dibenzodioxiny $x toxicita $7 D000072317
650    _2
$a financování organizované $7 D005381
651    _2
$a Česká republika $7 D018153
651    _2
$a Francie $7 D005602
651    _2
$a Maďarsko $7 D006814
700    1_
$a Stejskalová, Lucie $7 xx0142114
700    1_
$a Monostory, Katalin
700    1_
$a Maurel, Patrick
700    1_
$a Bachleda, Petr, $d 1954- $7 jn20020716344
700    1_
$a Pávek, Petr $7 xx0093070
700    1_
$a Dvořák, Zdeněk, $d 1974- $7 xx0118950
773    0_
$t Chemico-Biological Interactions $w MED00002111 $g Roč. 179, č. 2-3 (2009), s. 288-296
910    __
$a ABA008 $b x $y 2
990    __
$a 20110513105813 $b ABA008
991    __
$a 20110829144509 $b ABA008
999    __
$a ok $b bmc $g 839056 $s 702893
BAS    __
$a 3
BMC    __
$a 2009 $b 179 $c 2-3 $d 288-296 $m Chemico-biological interactions $n Chem Biol Interact $x MED00002111
LZP    __
$a 2011-2B09/jvme

Najít záznam